1Q EARNINGS: Actavis not done shopping for growth
This article was originally published in Scrip
Actavis isn't in the market for another mega-merger while it waits to close the $25bn acquisition of Forest Laboratories – unless, of course, the right deal comes along – but the long-time generic drug marketer and growing brand name pharmaceutical player is still shopping for assets that could boost the company's growth for the long term.
You may also be interested in...
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.
ICER’s final report on new acute migraine treatments said the drugs are similarly beneficial when patients don’t respond to or can’t take triptans, but found Reyvow is not as cost effective as Ubrelvy and rimegepant.
CEO Richard Pops said the company will leverage in-house expertise for internally and externally developed neuroscience assets, but partner selectively to advance its IL-2 protein in cancer.